Clinical and Translational Oncology

, Volume 10, Issue 11, pp 688–696

Langerhans cell histiocytosis

  • Joan Manel Gasent Blesa
  • Vicente Alberola Candel
  • Carlos Solano Vercet
  • Juan Laforga Canales
  • Christof Semler
  • M. Rosa Pérez Antolí
  • Carlos Rodríguez-Galindo
Educational Series

Abstract

Langerhans cell histiocytosis (LCH) is a poorly understood proliferative disease, with different patterns of clinical presentation. Currently it is classified according to the number and type of system involved and the degree of organ dysfunction. The aetiology of the disease remains uncertain, and in some cases the disease is polyclonal, suggesting a reactive condition. Many cytokines have been implicated in the pathogenesis of LCH. Different therapeutic approaches can be considered depending on the affected organ, including surgery, radiotherapy and chemotherapy. Long-term organ dysfunction may remain, despite disease control and/or eradication, making indefinite supportive treatment mandatory. Here we present a literature review on all of the aspects of the disease, treatment approaches and existing protocols, and finally an adult clinical case.

Keywords

Langerhans’s cell histiocytosis Adult Review 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arico M, Egeler RM (1998) Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 12:247–258PubMedCrossRefGoogle Scholar
  2. 2.
    Willman CL, Busque L, Griffith BB et al (1994) Langerhans’ cell histiocytosis (histiocytosis X) — a clonal proliferative disease. N Engl J Med 331: 154–160PubMedCrossRefGoogle Scholar
  3. 3.
    Broadbent V, Pritchard J, Davies EG (1984) Spontaneous remission of multisystem histiocytosis X. Lancet 1:253–254PubMedCrossRefGoogle Scholar
  4. 4.
    Kannourakis G, Abbas A (1994) The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer 70[Suppl 23]:S37–S40Google Scholar
  5. 5.
    Bernard F, Thomas C, Bertrand Y et al (2005) Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with hematological dysfunction. Eur J Cancer 41:2682–2689PubMedCrossRefGoogle Scholar
  6. 6.
    Writing Group of the Histiocyte Society (1987) Histiocytosis syndromes in children. Lancet 1:208Google Scholar
  7. 7.
    Favara BE, Feller AC, Pauli M et al (1997) Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29:157PubMedCrossRefGoogle Scholar
  8. 8.
    Favara BE (1991) Langerhans’ cell histiocytosis pathobiology and pathogenesis. Semin Oncol 18:3PubMedGoogle Scholar
  9. 9.
    Seiji M, Shimao K, Fitzpatrick TB, Birbeck MS (1961) The site of biosynthesis of mammalian tyrosinase. J Invest Dermatol 37:359PubMedGoogle Scholar
  10. 10.
    Valladeau J, Ravel O, Dezutter-Dambuyant C et al (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12:71PubMedCrossRefGoogle Scholar
  11. 11.
    Geissmann F, Lepelletier Y, Fraitag S et al (2001) Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 97:1241PubMedCrossRefGoogle Scholar
  12. 12.
    Jordan MB, McClain KL, Yan X et al (2005) Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer 44:251PubMedCrossRefGoogle Scholar
  13. 13.
    Egeler RM, Favara BE, van Meurs M et al (1999) Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94:4195PubMedGoogle Scholar
  14. 14.
    Egeler RM, Favara BE, Laman JD, Claassen E (2000) Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer 36:2105PubMedCrossRefGoogle Scholar
  15. 15.
    Ishii R, Morimoto A, Ikushima S et al (2006) High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 47:194PubMedCrossRefGoogle Scholar
  16. 16.
    Annels NE, Da Costa CE, Prins FA et al (2003) Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 197:1385PubMedCrossRefGoogle Scholar
  17. 17.
    De Filippi P, Badulli C, Cuccia M et al (2006) Specific polymorphisms of cytokine genes are associated with different risks to develop single-system or multi-system childhood Langerhans cell histiocytosis. Br J Haematol 132:784PubMedCrossRefGoogle Scholar
  18. 18.
    Fleming MD, Pinkus JL, Alexander SW et al (2003) Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood 101:2473PubMedCrossRefGoogle Scholar
  19. 19.
    Schouten B, Egeler RM, Leenen PJ et al (2002) Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 24:727PubMedCrossRefGoogle Scholar
  20. 20.
    Marchal J, Kambouchner M, Tazi A et al (2004) Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology 45:20PubMedCrossRefGoogle Scholar
  21. 21.
    Dina A, Zahava V, Iness M (2005) The role of vascular endothelial growth factor in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 27:62PubMedCrossRefGoogle Scholar
  22. 22.
    Schultz C, Klouche M, Friedrichsdorf S et al (1998) Langerhans cell histiocytosis in children: does soluble interleukin-2-receptor correlate with both disease extent and activity? Med Pediatr Oncol 31:61PubMedCrossRefGoogle Scholar
  23. 23.
    Rosso DA, Roy A, Zelazko M, Braier JL (2002) Prognostic value of soluble interleukin 2 receptor levels in Langerhans cell histiocytosis. Br J Haematol 117:54PubMedCrossRefGoogle Scholar
  24. 24.
    Rolland A, Guyon L, Gill M et al (2005) Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 174:3067PubMedGoogle Scholar
  25. 25.
    Bernstrand C, Carstensen H, Jakobsen B et al (2003) Immunogenetic heterogeneity in singlesystem and multisystem Langerhans cell histiocytosis. Pediatr Res 54:30PubMedCrossRefGoogle Scholar
  26. 26.
    McClain KL, Laud P, Wu WS, Pollack MS (2003) Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol 41:502PubMedCrossRefGoogle Scholar
  27. 27.
    Scappaticci S, Danesino C, Rossi E et al (2000) Cytogenetic abnormalities in PHA-stimulated lymphocytes from patients with Langerhans cell histiocytosis. AIEOP-Istiocitosi Group. Br J Haematol 111:258PubMedCrossRefGoogle Scholar
  28. 28.
    Leahy MA, Krejci SM, Friednash M et al (1993) Human herpes virus 6 is present in lesions of Langerhans cell histiocytosis. J Invest Dermatol 101:642PubMedCrossRefGoogle Scholar
  29. 29.
    Glotzbecker MP, Carpentieri DF, Dormans JP (2004) Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children. J Pediatr Orthop 24:123PubMedGoogle Scholar
  30. 30.
    McClain K, Jin H, Gresik V, Favara B (1994) Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol 47:16PubMedCrossRefGoogle Scholar
  31. 31.
    Shimakage M, Sasagawa T, Kimura M et al (2004) Expression of Epstein-Barr virus in Langerhans’ cell histiocytosis. Hum Pathol 35:862PubMedCrossRefGoogle Scholar
  32. 32.
    Baumgartner I, von Hochstetter A, Baumert B et al (1997) Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28:9PubMedCrossRefGoogle Scholar
  33. 33.
    Malpas JS, Norton AJ (1996) Langerhans cell histiocytosis in the adult. Med Pediatr Oncol 27:540PubMedCrossRefGoogle Scholar
  34. 34.
    Howarth DM, Gilchrist GS, Mullan BP et al (1999) Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 85:2278PubMedCrossRefGoogle Scholar
  35. 35.
    Islinger RB, Kuklo TR, Owens BD et al (2000) Langerhans’ cell histiocytosis in patients older than 21 years. Clin Orthop Relat Res 379:231–235PubMedCrossRefGoogle Scholar
  36. 36.
    Gotz G, Fichter J (2004) Langerhans’-cell histiocytosis in 58 adults. Eur J Med Res 9:510PubMedGoogle Scholar
  37. 37.
    Schonfeld N, Frank W, Wenig S et al (1993) Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 60:38PubMedCrossRefGoogle Scholar
  38. 38.
    Casolaro MA, Bernaudin JF, Saltini C et al (1988) Accumulation of Langerhans’ cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 137:406–411PubMedGoogle Scholar
  39. 39.
    Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258–261PubMedCrossRefGoogle Scholar
  40. 40.
    Aguayo SM, Kane MA, King TE Jr et al (1989) Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 84:1105–1113PubMedCrossRefGoogle Scholar
  41. 41.
    Del Rio M, Hernanz A, de la Fuente M (1994) Bombesin, gastrin-releasing peptide, and neuromedin C modulate murine lymphocyte proliferation through adherent accessory cells and activate protein kinase C. Peptides 15:15–22PubMedCrossRefGoogle Scholar
  42. 42.
    Lemaire I (1991) Bombesin-related peptides modulate interleukin-1 production by alveolar macrophages. Neuropeptides 20:217–223PubMedCrossRefGoogle Scholar
  43. 43.
    Youkeles LH, Grizzanti JN, Liao Z et al (1995) Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 151:145–150PubMedGoogle Scholar
  44. 44.
    Francus T, Klein RF, Staiano-Coico L et al (1988) Effects of tobacco glycoprotein (TGP) on the immune system. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J Immunol 140:1823–1829 [erratum 140:4413]PubMedGoogle Scholar
  45. 45.
    Tazi A, Moreau J, Bergeron A et al (1999) Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 163:3511PubMedGoogle Scholar
  46. 46.
    Yousem SA, Colby TV, Chen YY et al (2001) Pulmonary Langerhans’ cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 25:630PubMedCrossRefGoogle Scholar
  47. 47.
    Travis WD, Borok Z, Roum JH et al (1993) Pulmonary Langerhans cell granulomatosis (histiocytosis X): a clinicopathologic study of 48 cases. Am J Surg Pathol 17:971PubMedGoogle Scholar
  48. 48.
    Delobbe A, Durieu J, Duhamel A, Wallaert B (1996) Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X). Groupe d’Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J 9:2002Google Scholar
  49. 49.
    Crausman RS, Jennings CA, Tuder RM et al (1996) Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 153:426PubMedGoogle Scholar
  50. 50.
    Diette GB, Scatarige JC, Haponik EF et al (2005) Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration 72:134PubMedCrossRefGoogle Scholar
  51. 51.
    Soler P, Bergeron A, Kambouchner M et al (2000) Is high-resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis? Am J Respir Crit Care Med 162:264PubMedGoogle Scholar
  52. 52.
    Arzoo K, Sadeghi S, Pullarkat V (2001) Pamidrona te for bone pain from osteolytic lesions in Langerhans’-cell histiocytosis (letter). N Engl J Med 345:225PubMedCrossRefGoogle Scholar
  53. 53.
    Farran RP, Zaretski E, Egeler RM (2001) Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 23:54PubMedCrossRefGoogle Scholar
  54. 54.
    Brown RE (2001) Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis? Med Pediatr Oncol 36:641PubMedCrossRefGoogle Scholar
  55. 55.
    Fernández-Latorre F, Menor-Serrano F, Alonso-Charterina S, Arenas-Jiménez J (2000) Langerhans’ cell histiocytosis of the temporal bone in pediatric patients. AJR Am J Roentgenol 174: 217–221PubMedGoogle Scholar
  56. 56.
    Kamimura M, Kinoshita T, Itoh H et al (2000) Eosinophilic granuloma of the spine: early spontaneous disappearance of tumor detected on magnetic resonance imaging. J Neurosurg 93[2 Suppl]: 312–316PubMedGoogle Scholar
  57. 57.
    Guzey FK, Bas NS, Emel E et al (2003) Polyostotic monosystemic calvarial and spinal Langerhans cell histiocytosis treated by surgery and chemotherapy. Pediatr Neurosurg 38:206–211CrossRefGoogle Scholar
  58. 58.
    Egeler RM, Thompson RC, Voûte PA, Nesbit ME (1992) Intralesional infiltration of corticosteroids in localized Langerhans cell histiocytosis. J Pediatr Orthop 12:811–814PubMedGoogle Scholar
  59. 59.
    Weitzman S, Egeler RM (2008) Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr 20:23–29PubMedCrossRefGoogle Scholar
  60. 60.
    Munn S, Chu AC (1998) Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 12:269–286PubMedCrossRefGoogle Scholar
  61. 61.
    Kapur P, Erickson C, Rakheja D et al (2007) Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children’s Medical Center. J Am Acad Dermatol 56:290–294PubMedCrossRefGoogle Scholar
  62. 62.
    Braier J, Chantada G, Rosso D et al (1999) Langerhans cell histiocytosis: Retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol 16:377–385PubMedCrossRefGoogle Scholar
  63. 63.
    Willis B, Ablin A, Weinberg V et al (1996) Disease course and late sequelae of Langerhans’ cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 14: 2073–2082PubMedGoogle Scholar
  64. 64.
    Haupt R, Nanduri V, Calevo MG et al (2004) Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 42:438–444PubMedCrossRefGoogle Scholar
  65. 65.
    The French Langerhans’ Cell Histiocytosis Study Group (1996) A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 75:17–24Google Scholar
  66. 66.
    Mittheisz E, Seidl R, Prayer D (2007) Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 48:50–56PubMedCrossRefGoogle Scholar
  67. 67.
    Maghnie M, Cosi G, Genovese E et al (2000) Central diabetes insipidus in children and young adults. N Engl J Med 343:998–1007PubMedCrossRefGoogle Scholar
  68. 68.
    Municchi G, Marconcini S, D’Ambrosio A et al (2002) Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report. Pediatr Hematol Oncol 19:273–278PubMedCrossRefGoogle Scholar
  69. 69.
    Kaltsas GA, Powles TB, Evanson J et al (2000) Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological and radiological features and response to treatment. J Clin Endocr Metab 85: 1370–1376PubMedCrossRefGoogle Scholar
  70. 70.
    Maghnie M, Cosi G, Genovese E et al (2000) Central diabetes insipidus in children and young adults. N Engl J Med 343:998PubMedCrossRefGoogle Scholar
  71. 71.
    Maghnie M, Bossi G, Klersy C et al (1998) Dynamic endocrine testing and magnetic resonance imaging in the long-term follow-up of childhood Langerhans cell histiocytosis. J Clin Endocrinol Metab 83:3089PubMedCrossRefGoogle Scholar
  72. 72.
    Braunstein GD, Kohler PO (1972) Pituitary function in Hand Shuller Christian disease. N Engl J Med 286:1225–1229PubMedCrossRefGoogle Scholar
  73. 73.
    Dean HJ, Bishop A, Winter JS (1986) Growth hormone deficiency in patients with histiocytosis X. J Pediatr 109:615–618PubMedCrossRefGoogle Scholar
  74. 74.
    Nanduri VR, Bareille P, Pritchard J, Stanhope R (1986) Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol (Oxf) 53:509–515CrossRefGoogle Scholar
  75. 75.
    Donadieu J, Rolon MA, Pion I et al (2004) Incidence of growth hormone deficiency in pediatriconset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab 89:604–609PubMedCrossRefGoogle Scholar
  76. 76.
    Lahey ME (1975) Histiocytosis X: An analysis of prognostic factors. J Pediatr 87:184–189PubMedCrossRefGoogle Scholar
  77. 77.
    Komp DM, Herson J, Starling KA et al (1981) A staging system for Histiocytosis X: A Southwest Oncology Group Study. Cancer 47:798–800PubMedCrossRefGoogle Scholar
  78. 78.
    Montella L, Insabato L, Palmieri G (2004) Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Engl J Med 351:1034PubMedCrossRefGoogle Scholar
  79. 79.
    Saven A, Foon KA, Piro LD (1994) 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med 121:430PubMedGoogle Scholar
  80. 80.
    Weitzman S, Wayne AS, Arceci R et al (1999) Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 33:476PubMedCrossRefGoogle Scholar
  81. 81.
    Pardanani A, Phyliky RL, Li CY, Tefferi A (2003) 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 78:301PubMedGoogle Scholar
  82. 82.
    Womer RB, Anunciato KR, Chehrenama M (1995) Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol 25:70–73PubMedCrossRefGoogle Scholar
  83. 83.
    Munn SE, Olliver L, Broadbent V, Pritchard J (1999) Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 32:247–249PubMedGoogle Scholar
  84. 84.
    Farran RP, Zaretski E, Egeler RM (2001) Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 23:54–56PubMedCrossRefGoogle Scholar
  85. 85.
    Rodriguez-Galindo C, Kelly P, Jeng M et al (2002) Treatment of children with Langerhans Cell Histiocytosis with 2-Chlorodeoxyadenosine. Am J Hematol 69:179–184PubMedCrossRefGoogle Scholar
  86. 86.
    Choi SW, Bangaru BS, Wu CD, Finlay JL (2003) Gastrointestinal involvement in disseminated Langerhans cell histiocytosis with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine. J Pediatr Hematol Oncol 25:503–506PubMedCrossRefGoogle Scholar
  87. 87.
    Steiner M, Mathes-Martin S, Attarbaschi A et al (2005) Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 36:215–225PubMedCrossRefGoogle Scholar
  88. 88.
    Mogulkoc N, Veral A, Bishop PW et al (1999) Pulmonary Langerhans’ cell histiocytosis: radiologic resolution following smoking cessation. Chest 115:1452PubMedCrossRefGoogle Scholar
  89. 89.
    Reichle A, Vogt T, Kunz-Schughart L et al (2005) Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans’ cell histiocytosis of adults. Br J Haematol 128:730PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  • Joan Manel Gasent Blesa
    • 1
  • Vicente Alberola Candel
    • 2
  • Carlos Solano Vercet
    • 3
  • Juan Laforga Canales
    • 1
  • Christof Semler
    • 4
  • M. Rosa Pérez Antolí
    • 4
  • Carlos Rodríguez-Galindo
    • 5
  1. 1.Hospital General Universitari Marina AltaDènia, AlacantSpain
  2. 2.Hospital Universitari Arnau de VilanovaValènciaSpain
  3. 3.Hospital Clinic UniversitariValènciaSpain
  4. 4.Centro Clínico Euroclínica JàveaJàveaSpain
  5. 5.Department of OncologySt Jude Children’s Research HospitalMemphisUSA

Personalised recommendations